CoChat

Pharmacokinetic/pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation

Open access
Magee, Mindy He, Blum, Robert A., Lates, Christian D., Jusko, William J. · 2002 · British Journal of Clinical Pharmacology
Cited by 44

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Aims Mitogen‐induced ex vivo whole blood lymphocyte proliferation (WBLP) is a widely used method to assess lymphocyte responsiveness to immunosuppressive therapy. A three‐component complex model was developed to characterize effects of prednisolone on cell trafficking, transduction, and lymphocyte suppression. Methods An oral dose (0.27 mg kg−1) of prednisone was given to 32 subjects. The study consisted of baseline and prednisone phases each with 32 h of sampling. Measurements included plasma prednisolone concentrations,in vitro and ex vivo WBLP, and lymphocyte cell counts during baseline and prednisone phases. Results The final model consists of a precursor‐dependent indirect response model with a first‐order periodic influx rate for lymphocyte trafficking. This accounts for the rebound phenomenon and the circadian rhythm seen in all individual ex vivo WBLP effect‐time profiles. Prednisolone was modelled as inhibiting lymphocyte influx from the precursor to the blood pools. The direct suppressive effect of prednisolone on WBLP was modelled with the simple Imax model. A transduction step with rate constant ktwas introduced to the simple Imax model to account for the delay (∼4 h) in reaching the maximum inhibition. The I C50 values obtained ex vivo were circa 10 times lower than in vitro values (3.76 vs 38.8 ng ml−1), suggesting additional in vivo factors may have enhanced lymphocyte response to the inhibitory effect of prednisolone. Conclusions This integrated PK/PD model enables evaluation of multicomponent direct and indirect inhibition of ex vivo WBLP by steroids and other immunosuppressants in relation to sex and race.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2125.2002.01567.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 44

Metadata

Authors
Magee, M. H., Blum, R. A., Lates, C. D., & Jusko, W. J.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2002-05
Volume
53
Issue
5
Pages
474-484
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1942552234
Cited by
44
References
1
FWCI
0.72
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacokinetic/pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation. https://app.cochat.ai/papers/10.1046/j.1365-2125.2002.01567.x
The paper
Magee, M. H., Blum, R. A., Lates, C. D., & Jusko, W. J. (2002). Pharmacokinetic/pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation. British Journal of Clinical Pharmacology. https://doi.org/10.1046/j.1365-2125.2002.01567.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.